Method for treating coronary artery disease using antibody binding human protein tyrosine phosphatase beta(HPTPbeta)
View Patent ↗Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof.
1. A method of treating skeletal muscle or myocardial ischemia, stroke, coronary artery disease, or peripheral vascular disease, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof which binds HPTPbeta and regulates angiogenesis.
2. A method according to claim 1 , wherein the antibody is the monoclonal antibody R15E6 produced by hybridoma cell line ATCC No. PTA-7580 which binds to human protein tyrosine phosphatase beta (HPTPβ).
3. A method according to claim 1 , wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment, and an F(ab′) 2 fragment.
4. A method of enhancing Tie-2 signaling in a subject having skeletal muscle or myocardial ischemia, stroke, coronary artery disease, or peripheral vascular disease, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof which binds HPTPbeta and regulates angiogenesis.
5. A method according to claim 4 , wherein the antibody is the monoclonal antibody R15E6 produced by hybridoma cell line ATCC No. PTA-7580 which binds to human protein tyrosine phosphatase beta (HPTPβ).
6. A method according to claim 4 , wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment, and an F(ab′) 2 fragment.
7. A method for promoting endothelial cell migration in a subject having skeletal muscle or myocardial ischemia, stroke, coronary artery disease, or peripheral vascular disease, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof which binds HPTPbeta and regulates angiogenesis.
8. A method according to claim 7 , wherein the antibody is the monoclonal antibody R15E6 produced by hybridoma cell line ATCC No. PTA-7580 which binds to human protein tyrosine phosphatase beta (HPTPβ).
9. A method according to claim 7 , wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment, and an F(ab′) 2 fragment.
10. A method for promoting endothelial cell survival in a subject having skeletal muscle or myocardial ischemia, stroke, coronary artery disease, or peripheral vascular disease, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof which binds HPTPbeta and regulates angiogenesis.
11. A method according to claim 10 , wherein the antibody is the monoclonal antibody R15E6 produced by hybridoma cell line ATCC No. PTA-7580 which binds to human protein tyrosine phosphatase beta (HPTPβ).
12. A method according to claim 10 , wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment, and an F(ab′) 2 fragment.
13. A method for promoting blood vessel morphogenesis and blood vessel stabilization in a subject having skeletal muscle or myocardial ischemia, stroke, coronary artery disease, or peripheral vascular disease, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof which binds HPTPbeta and regulates angiogenesis.
14. A method according to claim 13 , wherein the antibody is the monoclonal antibody R15E6 produced by hybridoma cell line ATCC No. PTA-7580 which binds to human protein tyrosine phosphatase beta (HPTPβ).
15. A method according to claim 13 , wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment, and an F(ab′) 2 fragment.